ExploreWatchlistsPricing
  1. JP-listed companies
  3. Cash flow

(206A) Cash flow

Market cap
¥4.9B
P/E ratio
PRISM BioLab develops new drugs that target hard-to-reach protein interactions inside cells, partnering with major pharmaceutical companies like Eisai.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Income statementBalance sheetCash flowOther
2022/092023/092024/092025/09
Depreciation & amortization19--
Cash from operations 103-514150-1,468
Capital expenditures-6-35-206-65
Cash from investing -8-40-244-69
Cash from financing 111-3,37034
AI Chat